The Delhi High Court has held that Intas Pharmaceuticals’ mark CLAVIX constitutes pharmaceutical trademark infringement of Sanofi’s blockbuster heart drug mark PLAVIX, differing by just one letter. The court granted a permanent injunction and nominal damages of Rs. 20 lakhs, but dismissed Sanofi’s passing off claim for want of established goodwill in India in 2001.
Read more about The P-C Problem: Something that a Trademark Registry Search in 2001 could have prevented